Air Liquide   Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Paris France (1902)
Status: No NME R&D (1902)

Organization Overview

First Clinical Trial
2000
NCT00219713
First Marketed Drug
2013
oxygen
First NDA Approval
2013
oxygen
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AIR LIQUIDE AMERICA LP | AIR LIQUIDE AMERICA SPECIALITY GASES | AIR LIQUIDE CANADA INC | AIR LIQUIDE HEALTHCARE AMERICA CORP | AIR LIQUIDE LARGE INDUSTRIES US LP | Air Liquide SA | Air Liquide Santé International | AIR LIQUID INDUSTRIAL US LP

Active Ingredients

Marketed Drugs (4)

helium (2013)

nitrogen (2013 NDA)

nitrous oxide (2013)

oxygen (2013 NDA)

Drugs in Phase 4 Trials (10)

Key: Air Liquide (8) Acquired (2)

nitrogen (4 trials)

nitrous oxide (7 trials)

octenidine (4 trials)

ondansetron (zofran) (1 trial)

oxygen (10 trials)

phenoxyethyl alcohol (1 trial)

sevoflurane (ultane) (5 trials)

sodium chloride (1 trial)

urea (1 trial)

xenon xe-133 (7 trials)

Drugs in Phase 3 Trials (2)

helium (2 trials)

propofol (diprivan) (1 trial)

Drugs in Other Trials (2)

insulin human (humulin) (1 trial)

nitric oxide (inomax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Delirium (Phase 2)

Drug Hypersensitivity (Phase 3)

Hip Fractures (Phase 2)

Hyperalgesia (Phase 1)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Myocardial Ischemia (Phase 3)

Nausea (Phase 4)

Neoplasms (Phase 4)

Neuralgia (Phase 2)

Pain (Phase 3)

Postoperative Nausea and Vomiting (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Respiratory Aspiration (Phase 3)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial APIs: 14